EAGLE PHARMACEUTICALS, INC. Form SC 13G/A February 14, 2019

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934 (Amendment No. 4)*

Eagle Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, \$0.001 par value per share

(Title of Class of Securities)

269796108

(CUSIP Number)

December 31, 2018

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

o Rule 13d-1(b)

o Rule 13d-1(c)

x Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 2697961	08			13G
1	Name of Reporting Pers I.R.S. Identification No.		s (Entities Only)	
	Scott Tarriff			
2	Check the Appropriate Box if a Member of a Group* (a) 0			
	(b)	x (1)		
3	SEC Use Only			
4	Citizenship or Place of O United States	Organization		
	5		Sole Voting Power 784,419 (See Item 4 herein)	
Number of Shares Beneficially Owned by	6		Shared Voting Power 1,280,041 (See Item 4 herein)	
Each Reporting Person With	7		Sole Dispositive Power 784,419 (See Item 4 herein)	
	8		Shared Dispositive Power 1,280,041(See Item 4 herein)	
9	Aggregate Amount Beneficially Owned by Each Reporting Person 2,064,460 (See Item 4 herein)			
10	Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares* o			
11	Percent of Class Represented by Amount in Row (9) 14.31% (See Item 4 herein)			
12	Type of Reporting Perso IN	on*		

⁽¹⁾ This Schedule 13G is filed by Scott Tarriff, Tarriff 2016 Generation Skipping Exempt Family Trust DTD 12/28/2016 and Michael Graves (collectively, the Reporting Persons). The Reporting Persons expressly disclaim status as a group for purposes of this Schedule 13G.

²

CUSIP No. 269796	5108			13G
1	Name of Reporting Per I.R.S. Identification No		ns (Entities Only)	
	Tarriff 2016 Generation	n Skipping Exem	pt Family Trust DTD 12/28/2016	
2	Check the Appropriate (a) (b)	Box if a Member o x (1)	r of a Group*	
3	SEC Use Only			
4	Citizenship or Place of New Jersey	Organization		
	5		Sole Voting Power 0 (See Item 4 herein)	
Number of			0 (See Item 4 herein)	
Shares Beneficially Owned by	6		Shared Voting Power 1,103,680 (See Item 4 herein)	
Each Reporting Person With	7		Sole Dispositive Power 0 (See Item 4 herein)	
reison with	8		Shared Dispositive Power 1,103,680 (See Item 4 herein)	
9	Aggregate Amount Beneficially Owned by Each Reporting Person 1,103,680 (See Item 4 herein)			
10	Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares* o			
11	Percent of Class Represented by Amount in Row (9) 7.93% (See Item 4 herein)			
12	Type of Reporting Pers OO	son*		

⁽¹⁾ The Reporting Persons expressly disclaim status as a group for purposes of this Schedule 13G.

³

CUSIP No. 2697961	108			13G
1	Name of Reporting Pers I.R.S. Identification No.		s (Entities Only)	
	Michael Graves			
2	Check the Appropriate I (a) (b)	Box if a Member o o x (1)	of a Group*	
3	SEC Use Only			
4	Citizenship or Place of Output	Organization		
	5		Sole Voting Power 75,040(See Item 4 herein)	
Number of Shares Beneficially Owned by	6		Shared Voting Power 1,103,680 (See Item 4 herein)	
Each Reporting Person With	7		Sole Dispositive Power 75,040 (See Item 4 herein)	
	8		Shared Dispositive Power 1,103,680 (See Item 4 herein)	
9	Aggregate Amount Beneficially Owned by Each Reporting Person 1,178,720 (See Item 4 herein)			
10	Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares* o			
11	Percent of Class Represented by Amount in Row (9) 8.43% (See Item 4 herein)			
12	Type of Reporting Perso IN	on*		

(1) The Reporting Persons expressly disclaim status as a group for purposes of this Schedule 13G.

4

13G

CUSIP No. 269796108

Item 1.

Item 2.

Name of Issuer (a) Eagle Pharmaceuticals, Inc. (b) Address of Issuer s Principal Executive Offices 50 Tice Boulevard, Suite 315 Woodcliff Lake, NJ 07677 Name of Person Filing (a) Scott Tarriff, Tarriff 2016 Generation Skipping Exempt Family Trust DTD 12/28/2016, Michael Graves (together, the Reporting Persons) Address of Principal Business Office or, if none, Residence (b) The address for the principal business office of Scott Tarriff is: c/o Eagle Pharmaceuticals, Inc. 50 Tice Boulevard, Suite 315 Woodcliff Lake, NJ 07677 The address for the principal business office of the Tarriff 2016 Generation Skipping Exempt Family Trust DTD 12/28/2016 is: 1246 University Avenue West Suite 463 St. Paul, MN 55104 The address for the principal business office of Michael Graves is:

1246 University Avenue West

Suite 463

St. Paul, MN 55104

	Edg	ar Filing: EAGL	E PHARMACEUTICALS, INC Form SC 13G/A
		Citizenship Scott Tarriff - Uni	ted States
		Tarriff 2016 Gener	ration Skipping Exempt Family Trust DTD 12/28/2016 New Jersey
		Michael Graves -	
	(d)	Title of Class of S	
	(e)	CUSIP Number 269796108	0.001 par value per share (the Common Stock)
Item 3.	If this stateme Not applicable	tement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: able	
	(a)	0	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
	(b)	0	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
	(c)	0	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
	(d)	0	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).
	(e)	0	An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
	(f)	0	An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
	(g)	0	A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
	(h)	0	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
	(i)	0	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
	(j)	0	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J); Group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with
	(k)	0	§240.13d-1(b)(1)(ii)(J), please specify the type of institution:

5

Edgar Filing: EAGLE PHARMACEUTICALS, INC. - Form SC 13G/A

CUSIP No. 269796108

13G

Item 4. Ownership.

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount beneficially owned:

As of December 31, 2018, Mr. Tarriff beneficially owned 2,064,460 shares of the Issuer s Common Stock consisting of (i) 269,918 shares of Common Stock owned directly by him, (ii) 176,361 shares of Common Stock held by Janney Montgomery Scott LLC CUST FBO Scott Tarriff IRA for the Benefit of Mr. Tarriff (the IRA Trust), of which Mr. Tarriff is a trustee and, as such, may be deemed to share voting and dispositive power with respect to all shares held by the IRA Trust, (iii) options to purchase 514,501 shares of Common Stock held by the Tarriff 2016 Generation Skipping Exempt Family Trust DTD 12/28/2016 (the Family Trust) for the benefit of Mr. Tarriff s spouse and three children, of which Mr. Graves is the trustee, and as such, while Mr. Tarriff may be deemed to share voting and dispositive power with respect to all shares held by the Family Trust, Mr. Tarriff disclaims beneficial ownership with respect to such shares in the Family Trust, Mr. Tarriff disclaims beneficial ownership with respect to such shares in the Family Trust, except to the extent of his pecuniary interest therein. Mr. Tarriff s beneficial ownership does not include 63,000 shares of Common Stock underlying performance-based restricted stock units that are subject to vesting on January 1, 2021 to the extent that certain performance objectives are achieved.

As of December 31, 2018, Mr. Graves beneficially owned 1,178,720 shares of the Issuer s Common Stock consisting of (i) 1,000 shares of Common Stock owned directly by him, (ii) options to purchase 74,040 shares of Common Stock exercisable within 60 days of December 31, 2018 and (iii) 1,103,680 shares of Common Stock held by the Family Trust for the benefit of Mr. Tarriff s spouse and three children, of which Mr. Graves is the trustee. Mr. Graves disclaims any pecuniary interest with respect to such shares in the Family Trust. Percent of class:

For Mr. Tarriff: based on 13,914,025 shares of the Issuer s Common Stock issued and outstanding as of December 31, 2018 (which does not include 2,590,258 treasury shares) as reported by the Issuer to the Reporting Person and assumes the exercise of 514,501 options held by Mr. Tarriff that are exercisable within 60 days of December 31, 2018. As of December 31, 2018, the 2,064,460 shares of the Issuer s Common Stock beneficially owned by Mr. Tarriff represented 14.31% of such shares outstanding.

For the Tarriff 2016 Generation Skipping Exempt Family Trust DTD 12/28/2016: based on 13,914,025 shares of the Issuer s Common Stock issued and outstanding as of December 31, 2018 (which does not include 2,590,258 treasury shares) as reported by the Issuer to the Reporting Person. As of December 31, 2018, the 1,103,680 shares of the Issuer s Common Stock beneficially owned by the Tarriff 2016 Generation Skipping Exempt Family Trust DTD 12/28/2016 represented 7.93% of such shares outstanding.

For Mr. Graves: based on 13,914,025 shares of the Issuer s Common Stock issued and outstanding as of December 31, 2018 (which does not include 2,590,258 treasury shares) as reported by the Issuer to the Reporting Person and assumes the exercise of 74,040 options held by Mr. Graves that are exercisable within 60 days of December 31, 2018. As of December 31, 2018, the 1,178,720 shares of the Issuer s Common Stock beneficially owned by Mr. Graves represented 8.43% of such shares outstanding.

(c) Number of shares as to which the person has:

(b)

Edgar Filing: EAGLE PHARMACEUTICALS, INC. - Form SC 13G/A

(i)	Sole power to vote or to direct the vote:
	Scott Tarriff 784,419
	Tarriff 2016 Generation Skipping Exempt Family Trust DTD 12/28/2016 0
(ii)	Michael Graves 75,040 Shared power to vote or to direct the vote:
	Scott Tarriff 1,280,041
	Tarriff 2016 Generation Skipping Exempt Family Trust DTD 12/28/2016 1,103,680
(iii)	Michael Graves 1,103,680 Sole power to dispose or to direct the disposition of:
	Scott Tarriff 784,419
	Tarriff 2016 Generation Skipping Exempt Family Trust DTD 12/28/2016 0
(iv)	Michael Graves 75,040 Shared power to dispose or to direct the disposition of:
	Scott Tarriff 1,280,041
	Tarriff 2016 Generation Skipping Exempt Family Trust DTD 12/28/2016 1,103,680
	Michael Graves 1,103,680

Instruction. For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1).

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following o.

Item 6. Not applicable	Ownership of More than Five Percent on Behalf of Another Person.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.
Not applicable	
Item 8. Not applicable	Identification and Classification of Members of the Group.
Item 9. Not applicable	Notice of Dissolution of Group.
	6

Edgar Filing: EAGLE PHARMACEUTICALS, INC. - Form SC 13G/A

CUSIP No. 269796108

13G

Item 10. Not applicable Certification

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

February 14, 2019

By:

/s/ Scott Tarriff Scott Tarriff

Tarriff 2016 Generation Skipping Exempt Family Trust DTD 12/28/2016

By:	/s/
Name:	M
Title:	Tr

/s/ Michael Graves Michael Graves Trustee

By:

/s/ Michael Graves Michael Graves

7